Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Roche Holding AG (OtherRHHVF) and Amylyx Pharmaceuticals Inc (AMLX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report), Roche Holding AG (RHHVF – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hims & Hers Health (HIMS)
Bank of America Securities analyst Allen Lutz maintained a Sell rating on Hims & Hers Health yesterday and set a price target of $13.00. The company’s shares closed last Thursday at $15.82, close to its 52-week low of $11.20.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Hims & Hers Health has an analyst consensus of Hold, with a price target consensus of $32.39, representing a 102.3% upside. In a report issued on February 9, Citi also maintained a Sell rating on the stock with a $16.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Roche Holding AG (RHHVF)
In a report released today, Graham Parry from Citi maintained a Buy rating on Roche Holding AG, with a price target of CHF400.00. The company’s shares closed last Thursday at $477.44.
Parry has an average return of
According to TipRanks.com, Parry is ranked #6660 out of 12109 analysts.
Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $446.75, implying a -8.6% downside from current levels. In a report issued on February 9, Barclays also maintained a Buy rating on the stock with a CHF410.00 price target.
Amylyx Pharmaceuticals Inc (AMLX)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $19.00. The company’s shares closed last Thursday at $14.02.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Amylyx Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.50, a 60.7% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $19.00 price target.
